Navigation Links
UF scientists discover new explanation for controversial old patient-care technique
Date:10/20/2009

GAINESVILLE, Fla. You might not know what it's called, but if you've had general anesthesia before surgery, especially after an accident, it is likely you have received Sellick's maneuver. That's when fingers are pressed against a patient's throat to prevent regurgitation and spilling of stomach contents into the airway and lungs while anesthesia is being administered.

Such regurgitation could result in serious lung damage and even death.

The maneuver is a longstanding practice, first described in 1961 by British physician Brian Sellick. Performed dozens of times a day in hospitals, the procedure is accepted as "standard of care" and is a basic skill taught in all anesthesiology training programs. Anesthesiologists estimate conservatively that more than 100,000 people a year undergo the procedure.

But recently some physicians have begun to question the technique in the wake of a study challenging its effectiveness and ease of execution. And some have stopped using it altogether.

Now, researchers from University of Florida College of Medicine have used magnetic resonance imaging of the neck region to show that the maneuver works and that doubts about its effectiveness are based on a misunderstanding of what physical changes happen in the neck during the procedure.

"Sellick was right that the maneuver works but he was a bit off on the anatomy," said UF anesthesiologist Mark J. Rice, M.D., who led the study now online and to be featured on the cover of the November edition of the journal Anesthesia & Analgesia. The journal will also include two editorials on the controversial topic side by side with the UF paper, which has been selected by the editorial board as this month's graduate medical education article for November.

Also called cricoid pressure, the eponymous maneuver has for decades been described as the pinching of the esophagus between the cricoid a ring of cartilage that surrounds the trach
'/>"/>

Contact: Czerne M. Reid
czerne@ufl.edu
352-273-5810
University of Florida
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. UF receives $12.2 million to establish national network of scientists
2. Caltech scientists create robot surrogate for blind persons in testing visual prostheses
3. Time in a bottle: Scientists watch evolution unfold
4. Scientists demonstrate link between genetic defect and brain changes in schizophrenia
5. Scientists remove amyloid plaques from brains of live animals with Alzheimers disease
6. UNC scientists win $1.6 million stimulus award to accelerate decoding of human genome
7. Scientists urge EPA to adopt systems thinking
8. Scientists identify common HPV genotypes in northern India, encourage vaccination
9. Scientists take step toward simple and portable tuberculosis tests for developing world
10. Too much of a good thing? Scientists explain cellular effects of vitamin A overdose and deficiency
11. MDC scientists show how hematopoietic stem cell development is regulated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2015)... TRIANGLE PARK, North Carolina , 5. ... sein 35. Jahr als spezialisiertes Logistikunternehmen und ... Position als einzige klinische Logistikfirma (Clinical Logistics ... Die Kernbotschaft der neuen Kampagne lautet ... und Lieferungen. Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... OXFORD, Conn. , Jan. 26, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... a new corporate website ( http://www.nxt-id.com/ ) as part ... Wocket™ smart wallet. The Company launched its new consumer ... Gino Pereira , CEO of NXT-ID said, "Our ...
(Date:2/5/2015)... OXFORD, Conn. , Jan. 28, 2015 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... present at the upcoming RedChip Global Online CEO Conference ... Gino Pereira , CEO of ... discussing its lead product, the Wocket smart wallet and ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3
... drinking water in Bangladesh called the "largest mass ... Health Organization and known to be responsible for a ... to have an immediate and toxic effect on the ... is the first to identify a dramatic present-day consequence ...
... HARBOR, N.Y. (Nov. 30, 2010) -- The nucleus of ... DNA replication, transcription, and RNA processing take place. Within the ... according to the functional demands of the cell. "The ... is arguably one of the most exciting fields of contemporary ...
... For Immediate Release A team of scientists from The ... in the body,s response to eliminate pathogens, such as bacteria ... field of immunology and have potential implications for far-ranging topics ... autoimmunity. The results of the study, led by Scripps ...
Cached Biology News:Arsenic-polluted water toxic to Bangladesh economy 2Arsenic-polluted water toxic to Bangladesh economy 3Arsenic-polluted water toxic to Bangladesh economy 4Scripps Research scientists redefine the role of plasma cells in the immune system 2Scripps Research scientists redefine the role of plasma cells in the immune system 3Scripps Research scientists redefine the role of plasma cells in the immune system 4
(Date:2/27/2015)... Halifax, Nova Scotia (PRWEB) February 27, 2015 ... clinical stage vaccine and immunotherapy company, today announced ... approved its application for Fast Track designation and ... DPX-Ebola vaccines, in conjunction with the mutual co-development ... had previously obtained Fast Track designation for the ...
(Date:2/27/2015)... Cytokinetics, Incorporated (Nasdaq: CYTK) announced today ... patients and health care advocates in the United States ... Rare Disease Day is dedicated to elevating public ... special challenges faced by patients with rare diseases and ... to stand alongside patients and caregivers representing the rare ...
(Date:2/26/2015)... , Feb. 26, 2015  23andMe, the leading personal ... Black as Privacy Officer and Corporate Counsel. Black ... privacy laws as well as health care regulations. As ... will be responsible for reviewing, updating and enhancing the ... U.S. and abroad. She joined the company January 5, ...
(Date:2/26/2015)... LAUDERDALE, Fla. , Feb. 26, 2015 ... discussed growth priorities driven by key research advancements and ... segments at today,s Bank of America Merrill Lynch 2015 ... met the challenge of building grain supplies the last ... to continue at the pace of the last decade, ...
Breaking Biology Technology:Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 623andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5
... FRAMINGHAM, Mass. and SYDNEY, Nov. 18, 2010 HeartWare ... a leading innovator of less invasive, miniaturized circulatory support ... failure, today announced that CEO Doug Godshall is scheduled ... Piper Jaffray Health Care Conference on Tuesday, November 30, ...
... Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed ...
... Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
Cached Biology Technology:HeartWare to Present at the 22nd Annual Piper Jaffray Health Care Conference 2Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 2Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 3Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 4Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 5Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 6Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 7Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 8Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 9Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 10Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 2Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 3Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 4Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 5Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 6Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 7Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 8Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 9Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 10Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 11
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. Material: polystyrene flat ...
Comp Dim: chamber diam. depth 20 2.8 mm chamber maximum volume 720 μL...
... for in vitro diagnostic assays, all EIA/RIA ... for uniform binding, high optical clarity and ... are part of the Certified Surface Chemistry ... be within QA release specifications. Linkage: This ...
... clarification reagent; Ideal for clarifying many ... proteins, nucleic acids, & proteoglycans; Contains ... improves downstream processing; Utilizes a reagent ... supplied as a suspension in saline; ...
Biology Products: